NCT07088926 - A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization | Biotech Hunter

Enrollment

435

Participants

Timeline

Start Date

November 12, 2025

Primary Completion Date

December 9, 2027

Study Completion Date

June 14, 2028

Conditions

Bronchiectasis With Pseudomonas Aeruginosa Colonization

Interventions

BIOLOGICAL

AZD0292

AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

OTHER

Placebo

Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

Trial Locations (18)

3000

Research Site, Leuven

4000

Research Site, Liège

9000

Research Site, Ghent

9100

Research Site, Sint-Niklaas

28040

Research Site, Madrid

29631

Research Site, Benalmádena

34362

Research Site, Haifa

42300

Research Site, Bandar Puncak Alam

46020

Research Site, Valencia

52621

Research Site, Ramat Gan

59100

Research Site, Kuala Lumpur

60596

Research Site, Frankfurt

76063

Research Site, Mansfield

91031

Research Site, Jerusalem

6423906

Research Site, Tel Aviv

7830604

Research Site, Ashkelon

08036

Research Site, Barcelona

06800

Research Site, Mérida